Summit Trail Advisors LLC Buys New Holdings in iCAD, Inc. (NASDAQ:ICAD)

Summit Trail Advisors LLC purchased a new position in iCAD, Inc. (NASDAQ:ICAD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 117,000 shares of the technology company’s stock, valued at approximately $214,000. Summit Trail Advisors LLC owned 0.44% of iCAD at the end of the most recent reporting period.

Separately, waypoint wealth counsel boosted its position in shares of iCAD by 44.0% during the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after acquiring an additional 4,400 shares during the last quarter. Institutional investors own 24.61% of the company’s stock.

iCAD Trading Up 1.7 %

Shares of ICAD stock opened at $3.53 on Thursday. The stock has a market capitalization of $93.69 million, a price-to-earnings ratio of -27.15 and a beta of 1.47. iCAD, Inc. has a 12-month low of $1.18 and a 12-month high of $3.78. The stock’s 50-day moving average price is $2.27 and its 200-day moving average price is $1.85.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of iCAD from a “hold” rating to a “sell” rating in a report on Wednesday.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.